iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/32365729/
Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 29;8(5):651.
doi: 10.3390/microorganisms8050651.

Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward

Adam Clark  1 , Daniel N Wolfe  1
Affiliations
Review

Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward

Adam Clark et al. Microorganisms. .

Abstract

A licensed anthrax vaccine has been available for pre-exposure prophylaxis in the United States since 1970, and it was approved for use as a post-exposure prophylaxis, in combination with antibiotic treatment, in 2015. A variety of other vaccines are available in other nations, approved under various regulatory frameworks. However, investments in anthrax vaccines continue due to the severity of the threat posed by this bacterium, as both a naturally occurring pathogen and the potential for use as a bioweapon. In this review, we will capture the current landscape of anthrax vaccine development, focusing on those lead candidates in clinical development. Although approved products are available, a robust pipeline of candidate vaccines are still in development to try to address some of the key research gaps in the anthrax vaccine field. We will then highlight some of the most pressing needs in terms of anthrax vaccine research.

Keywords: Bacillus; anthracis; anthrax; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kamal S., Rashid A.K.M.M., Bakar M.A., Ahad M.A. Anthrax: An Update. Asian Pac. J. Trop. Biomed. 2011;1:496–501. doi: 10.1016/S2221-1691(11)60109-3. - DOI - PMC - PubMed
    1. Goel A. Anthrax: A disease of biowarfare and public health importance. World J. Clin. Cases. 2015;3:20–33. doi: 10.12998/wjcc.v3.i1.20. - DOI - PMC - PubMed
    1. Keim P., Smith K.L., Keys C., Takahashi H., Kurata T., Kaufmann A. Molecular Investigation of the Aum Shinrikyo Anthrax Release in Kameido, Japan. J. Clin. Microbiol. 2001;39:4566–4567. doi: 10.1128/JCM.39.12.4566-4567.2001. - DOI - PMC - PubMed
    1. Zacchia N.A., Schmitt K. Medical Spending for the 2001 Anthrax Letter Attacks. Disaster Med. Public Health Prep. 2019;13:539–546. doi: 10.1017/dmp.2018.113. - DOI - PubMed
    1. Schmitt K., Zacchia N.A. Total Decontamination Cost of the Anthrax Letter Attacks. Biosecur. Bioterror. 2012;10:98–109. doi: 10.1089/bsp.2010.0053. - DOI - PubMed

LinkOut - more resources